Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine, Inc. (NASDAQ: IRON) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its clinical-stage biopharmaceutical business focused on serious hematologic diseases. These SEC filings cover financial results, capital-raising transactions, regulatory milestones, and key corporate events related to the company’s investigational programs in red blood cell biology, heme biosynthesis, and iron homeostasis.
Among the most frequently referenced documents are current reports on Form 8-K, where Disc Medicine discloses material events such as quarterly financial results, public offerings of common stock and pre-funded warrants, and significant regulatory developments. For example, the company has used 8-K filings to report a Commissioner’s National Priority Voucher from the U.S. Food and Drug Administration for bitopertin in erythropoietic protoporphyria, the submission of a New Drug Application under the accelerated approval pathway, and the terms of an underwriting agreement for an upsized public offering intended to support operations and development plans.
Investors also look to Disc Medicine’s periodic reports on Forms 10-K and 10-Q for comprehensive discussions of its pipeline, including bitopertin, DISC-0974, and DISC-3405, as well as risk factors and management’s analysis of financial condition. Filings may describe clinical trial status, patent coverage such as composition of matter protection for DISC-0974, and the company’s expectations regarding cash runway based on existing cash, cash equivalents, marketable securities, and offering proceeds.
On this page, users can access Disc Medicine’s SEC filings as they are made available through EDGAR. AI-powered tools can help summarize lengthy documents, highlight key sections on topics such as clinical development, financing terms, and forward-looking statements, and make it easier to understand how individual filings relate to the company’s broader strategy and risk profile. Forms 10-K, 10-Q, and 8-K, along with exhibits, provide the primary regulatory record for IRON and are central to in-depth fundamental research.
Disc Medicine, Inc. furnished an update on its liquidity, stating that preliminary unaudited cash, cash equivalents and marketable securities totaled approximately $791 million as of December 31, 2025. This figure is an estimate and may change once the year-end financial close and audit procedures are completed, so it is not a substitute for the company’s upcoming Form 10-K.
The company also highlighted recent achievements and key business objectives and milestones for 2026 and is sharing further details through a press release and an investor presentation. Disc Medicine plans to use these materials during its participation in the 44th Annual J.P. Morgan Healthcare Conference, including a scheduled investor presentation on January 14, 2026.
Disc Medicine, Inc. received a Schedule 13G reporting that RA Capital entities and their principals hold a significant minority stake in the company. RA Capital Healthcare Fund, L.P. directly holds 2,228,924 shares of Disc Medicine common stock, which the reporting group states represents 5.9% of the outstanding common shares, based on 37,750,162 shares outstanding as of October 31, 2025.
RA Capital Management, L.P. is the investment adviser to the fund and, along with Peter Kolchinsky and Rajeev Shah, may be deemed a beneficial owner for Section 13(d) purposes through its control of voting and investment decisions. The fund has delegated sole voting and dispositive power over its holdings to RA Capital and disclaims beneficial ownership except for regulatory reporting. The filers certify the shares were not acquired to change or influence control of Disc Medicine.
Disc Medicine, Inc. director reported several small sales of the company’s common stock on 12/17/2025. The transactions involved indirect holdings through Atlas Venture-managed funds. One fund sold 393 shares, leaving 349,210 shares beneficially owned following the sale. A second fund sold 213 shares, with 337,485 shares remaining, and a third fund sold 148 shares, with 14,013 shares remaining.
The weighted average sale price reported for these trades was $91.47 per share, with individual trades executed between $91.2501 and $91.52. The director reports these positions as indirectly owned through Atlas Venture Opportunity Fund I, Atlas Venture Opportunity Fund II, and Atlas Venture Fund XII and disclaims beneficial ownership beyond any pecuniary interest.
A director of Disc Medicine, Inc. reported multiple December 2025 transactions in the company’s common stock. The filing lists several sales coded 'S' on 12/12, 12/15, and 12/16/2025 at weighted average prices including $92.05, $92.58, $93.8, $91.18, $92.01, $91.87, and $91.24 per share.
On 12/15/2025 the director exercised a fully vested stock option for 7,000 shares at an exercise price of $13.5 per share and sold those 7,000 shares the same day at a weighted average price of $91.87 per share. After the 12/16/2025 sales, the director reports indirect beneficial ownership of 349,603 Disc Medicine shares through Atlas Venture Opportunity Fund I, 337,698 shares through Atlas Venture Opportunity Fund II, and 14,161 shares through Atlas Venture Fund XII, while disclaiming beneficial ownership beyond any pecuniary interest.
Disc Medicine, Inc. reported that a company officer serving as Chief Medical Officer sold shares of common stock on 12/15/2025 in open-market transactions executed under a Rule 10b5-1 trading plan adopted on June 26, 2025.
The sales included 3,642 shares at a weighted average price of $90.6037 (with trades between $90.02 and $90.97), 9,151 shares at a weighted average price of $91.4353 (with trades between $91.03 and $91.99), and 300 shares at $92.23.
After these transactions, the reporting person directly beneficially owned 75,702 shares of Disc Medicine common stock.
Disc Medicine, Inc.’s chief executive officer and director reported a series of equity transactions on December 11, 2025. On that date, the insider exercised stock options to acquire 40,000 shares of common stock at a price of $9.86 per share, then sold 40,000 common shares in multiple market trades at weighted average prices detailed in the footnotes.
The activity was carried out under a Rule 10b5-1 trading plan adopted on February 13, 2025. After these transactions, the insider directly beneficially owned 171,828 shares of Disc Medicine common stock and held 75,375 stock options that remain beneficially owned following the reported exercise.
Disc Medicine, Inc. (IRON) reported an insider transaction by its Chief Operating Officer on 11/11/2025. The officer exercised a stock option for 30,000 shares at $2.65 and executed pre‑planned sales under a Rule 10b5‑1 trading plan adopted on July 22, 2025.
The sales occurred in four tranches: 8,015 shares at a weighted average price of $83.1453, 4,585 shares at $83.9877, 9,360 shares at $85.3301, and 8,040 shares at $85.9129. Following these transactions, the officer beneficially owned 40,555 shares directly. The option carried an exercise price of $2.65 and is shown as fully vested, with an expiration of 08/10/2030; 7,941 derivative securities remained beneficially owned after the transactions.
Disc Medicine (IRON) reported Q3 2025 results showing continued investment in its hematology pipeline. Net loss was
R&D expense was
Subsequent to quarter‑end, an underwritten offering on
Disc Medicine, Inc. (IRON) furnished an update on its business by announcing financial results for the third quarter ended September 30, 2025, and providing a corporate update. The details are contained in a press release furnished as Exhibit 99.1.
The information under Item 2.02 is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act, and it is not incorporated by reference into other filings unless expressly stated. The company’s common stock trades on the Nasdaq Global Market under the symbol IRON.
Disc Medicine (IRON): insider sale disclosed. AI DMI LLC, identified as a director and 10% owner, reported selling 744,047 shares of Disc Medicine common stock on October 22, 2025 at $80.47 per share. The sale was executed as part of an underwritten secondary offering.
Following this transaction, the reporting persons show beneficial ownership of 2,814,379 shares held directly. The filing notes Access Industries affiliates and Len Blavatnik may be deemed beneficial owners through control relationships, with each disclaiming beneficial ownership except to the extent of any pecuniary interest.
FAQ
What is the current stock price of Disc Medicine (IRON)?
What is the market cap of Disc Medicine (IRON)?
